The Multidisciplinary Matrix: Management of Prostate Cancer, 2nd edition
There is no single “correct” way to treat prostate cancer. A 60-year-old with a Gleason 9 tumor requires massive, immediate intervention; a 75-year-old with a Gleason 6 tumor requires nothing but active surveillance. Management of Prostate Cancer: A Multidisciplinary Approach, 2nd edition is a fiercely pragmatic, debate-driven clinical manual detailing how to navigate this chaotic treatment landscape. This volume provides the exact collaborative blueprints required when urologists, radiation oncologists, and medical oncologists violently disagree on the best approach.
Mastering the Castration-Resistant Transition
The core philosophy of this text is managing tumor evolution. The authors aggressively detail the failure of Androgen Deprivation Therapy (ADT). It dictates exactly how a prostate tumor, initially starved by testosterone blockade, will eventually mutate to generate its *own* testosterone internally, becoming Castration-Resistant Prostate Cancer (CRPC), and detailing the exact moment the medical oncologist must intervene with next-generation anti-androgens like enzalutamide or abiraterone.
Navigating the Post-Surgical Recurrence
The book provides a masterclass in salvage therapy. It dictates the exact clinical pathways for the rising PSA. It rigorously explores the anxiety of biochemical recurrence after a radical prostatectomy, explaining exactly how to interpret a PSA that climbs from 0.0 to 0.2, and detailing the absolute necessity of administering salvage radiation to the pelvic bed before the PSA reaches 0.5 to maximize the chance of a secondary cure.
Frequently Asked Questions (FAQs)
Does this book advocate for surgery over radiation?
No, it is explicitly *multidisciplinary*, providing unbiased, data-driven comparisons between robotic prostatectomy, brachytherapy, external beam radiation, and active surveillance.
Who is the primary audience?
It is the absolute, mandatory debate forum for Urologists, Medical Oncologists, Radiation Oncologists, and Multidisciplinary Tumor Boards.
